Login Register Cart 0
Generic placeholder image

Current Indian Science

Editor-in-Chief

ISSN (Print): 2210-299X
ISSN (Online): 2210-3007

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

Current Regulatory Framework and Challenges for the Approval of Complex Generics in the US and the EU

Author(s): Sharvari Patil, Sandeep Kumar*, Dasari Mallikarjuna Rao* and Kishore Rewatkar*

Volume 2, 2024

Published on: 08 December, 2023

Article ID: e2210299X269535 Pages: 17

DOI: 10.2174/012210299X269535231203164108

Price: $

Abstract

The pharmaceutical industry is witnessing a growing demand for complex generic products, which are generic versions of drugs that possess complex formulations, delivery systems, or active ingredients. However, the approval process for these complex generic products poses unique challenges compared to traditional generics. There is no specific regulatory procedure available for the approval of complex generics, unlike smallmolecule generics and biosimilars. This led to controversial arguments in the past about the scientific evidence needed for applications, which led to lengthy approval processes. The regulatory frameworks that are currently being used for complex generics are debatable and unclear. Complexity in the molecular structure, mechanism of action, route of delivery, and complex manufacturing process makes proving bioequivalence and pharmaceutical equivalence difficult. There is a need for harmonization of the regulatory framework by the agencies to help the generic manufacturers by providing scientific advice, defining the submission requirements for complex products, and fastening the approval process.

This review begins by discussing the regulatory landscape surrounding complex generic products in various regions, including the United States and Europe. It examines the specific guidelines and requirements set forth by regulatory authorities to ensure the safety, efficacy, and quality of these products. Additionally, the review explores the differences in terminology and definitions used to classify complex generics across different jurisdictions. Furthermore, it delves into the challenges faced by both regulatory agencies and pharmaceutical companies in evaluating and approving complex generic products. These challenges include establishing appropriate bioequivalence criteria, determining interchangeability with the reference product, addressing patent and exclusivity issues, and ensuring consistent quality throughout the product lifecycle. The impact of these challenges on market entry and competition is also discussed. The review highlights the need for harmonization and streamlining of regulations for complex generic products worldwide. It emphasizes the importance of clear and consistent guidelines to enable timely approvals, foster innovation, and facilitate patient access to affordable alternatives.

[1]
Complex Generics News | FDA. Available from: https://www.fda.gov/drugs/generic-drugs/complex-generics-news
[2]
Mühlebach, S. Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach? Adv. Drug Deliv. Rev., 2018, 131, 122-131.
[http://dx.doi.org/10.1016/j.addr.2018.06.024] [PMID: 29966685]
[3]
Yan, M.; Zhou, J. Suprasomes: An Emerging Platform for Cancer Theranostics. Sci. China Chem., 2023, 66(3), 613-614.
[http://dx.doi.org/10.1007/S11426-022-1477-X/METRICS]
[4]
Zhou, J.; Rao, L.; Yu, G.; Cook, T.R.; Chen, X.; Huang, F. Supramolecular cancer nanotheranostics. Chem. Soc. Rev., 2021, 50(4), 2839-2891.
[http://dx.doi.org/10.1039/D0CS00011F] [PMID: 33524093]
[5]
Yan, M.; Wu, S.; Wang, Y.; Liang, M.; Wang, M.; Hu, W.; Yu, G.; Mao, Z.; Huang, F.; Zhou, J. Recent progress of supramolecular chemotherapy based on host–guest interactions. Adv. Mater., 2023, 2304249, 2304249.
[http://dx.doi.org/10.1002/adma.202304249] [PMID: 37478832]
[6]
Tang, G.; He, J.; Liu, J.; Yan, X.; Fan, K.; Yan, X. Nanozyme for tumor therapy: Surface modification matters. Exploration, 2021, 1(1), 75-89.
[http://dx.doi.org/10.1002/EXP.20210005] [PMID: 37366468]
[7]
Marquardt, J.L.; Auten, S.R. Strategic considerations under the Biologics Price Competition and Innovation Act. Expert Opin. Ther. Pat., 2013, 23(8), 915-918.
[http://dx.doi.org/10.1517/13543776.2013.813935] [PMID: 23829693]
[8]
Stern, S.; Coghlan, J.; Krishnan, V.; Raney, S.G.; Babiskin, A.; Jiang, W.; Lionberger, R.; Xu, X.; Schwendeman, A.; Polli, J.E. Research and education needs for complex generics. Pharm. Res., 2021, 38(12), 1991-2001.
[http://dx.doi.org/10.1007/s11095-021-03149-y] [PMID: 34950975]
[9]
Kirchhoff, C.F.; Wang, X.Z.M.; Conlon, H.D.; Anderson, S.; Ryan, A.M.; Bose, A. Biosimilars: Key regulatory considerations and similarity assessment tools. Biotechnol. Bioeng., 2017, 114(12), 2696-2705.
[http://dx.doi.org/10.1002/bit.26438] [PMID: 28842986]
[10]
Verbeeck, R.K. Bioequivalence, therapeutic equivalence and generic drugs. Acta Clin. Belg., 2009, 64(5), 379-383.
[http://dx.doi.org/10.1179/acb.2009.063] [PMID: 19999384]
[11]
Klein, K.; Stolk, P.; De Bruin, M.L.; Leufkens, H.G.M.; Crommelin, D.J.A.; De Vlieger, J.S.B. The EU regulatory landscape of non-biological complex drugs (NBCDs) follow-on products: Observations and recommendations. Eur. J. Pharm. Sci., 2019, 133, 228-235.
[http://dx.doi.org/10.1016/j.ejps.2019.03.029] [PMID: 30953753]
[12]
Hussaarts, L.; Mühlebach, S.; Shah, V.P.; McNeil, S.; Borchard, G.; Flühmann, B.; Weinstein, V.; Neervannan, S.; Griffiths, E.; Jiang, W.; Wolff-Holz, E.; Crommelin, D.J.A.; de Vlieger, J.S.B. Equivalence of complex drug products: advances in and challenges for current regulatory frameworks. Ann. N. Y. Acad. Sci., 2017, 1407(1), 39-49.
[http://dx.doi.org/10.1111/nyas.13347] [PMID: 28445611]
[13]
Tinkle, S.; McNeil, S.E.; Mühlebach, S.; Bawa, R.; Borchard, G.; Barenholz, Y.C.; Tamarkin, L.; Desai, N. Nanomedicines: addressing the scientific and regulatory gap. Ann. N. Y. Acad. Sci., 2014, 1313(1), 35-56.
[http://dx.doi.org/10.1111/nyas.12403] [PMID: 24673240]
[14]
First Generic Version of NuvaRing Gets FDA Approval - MPR. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/formal-meetings-between-fda-and-anda-applicants-complex-products-under-gdufa-guidance-industry
[15]
Lunawat, S.; Bhat , K. Complex Generic Products: Insight of current regulatory frameworks in us, eu and canada and the need of harmonisation. Ther Innov Regul Sci., 2020, 54(5), 991-1000.
[16]
Burgess, DJ.; Hussain, AS.; Ingallinera, TS.; Chen, ML. Assuring quality and performance of sustained and controlled release parenterals: Workshop report. AAPS PharmSci., 2002, 4(2)
[17]
Fda, Cder. Sameness Evaluations in an ANDA-Active Ingredients Guidance for industry draft guidance. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/andas-certain-highly-purified-synthetic-peptide-drug-products-refer-listed-drugs-rdna-origin
[18]
Zhang, D. Comparative Analyses and Related Comparative Use Human Factors Studies for a Drug-Device Combination Product Submitted in an ANDA: Draft Guidance for Industry. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/comparative-analyses-and-related-comparative-use-human-factors-studies-drug-device-combination (Accessed 2023-05-24).
[19]
O’Brien, M.N.; Jiang, W.; Wang, Y.; Loffredo, D.M. Challenges and opportunities in the development of complex generic long-acting injectable drug products. J. Control. Release, 2021, 336, 144-158.
[http://dx.doi.org/10.1016/j.jconrel.2021.06.017] [PMID: 34126170]
[20]
Holloway, C.; Mueller-Berghaus, J.; Lima, B.S.; Lee, S.L.; Wyatt, J.S.; Nicholas, J.M.; Crommelin, D.J.A. Scientific considerations for complex drugs in light of established and emerging regulatory guidance. Ann. N. Y. Acad. Sci., 2012, 1276(1), 26-36.
[http://dx.doi.org/10.1111/j.1749-6632.2012.06811.x] [PMID: 23193987]
[21]
Osterhout, JL. Draft guidance on sevelamer carbonate. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022127s000TOC.cfm2017.
[22]
Gonella, A.; Grizot, S.; Liu , F.; López , N.A. Long-acting injectable formulation technologies: Challenges and opportunities for the delivery of fragile molecules, 2022, 19(8), 927-944.
[23]
Jose, V.; Oza, B.; Radhakrishna, S.; Pipalava, P. Pharmacovigilance of biosimilars – Why is it different from generics and innovator biologics? J. Postgrad. Med., 2019, 65(4), 227-232.
[http://dx.doi.org/10.4103/jpgmM_109_19] [PMID: 31571620]
[24]
Fda; Cder. Sameness Evaluations in an ANDA-Active Ingredients Guidance for Industry DRAFT GUIDANCE 2002.
[25]
Zhang, D. Session I: Demonstrating Complex API Sameness. 2017.
[26]
Jiang, X. Introduction to Complex Products and FDA Considerations Demonstrating Equivalence of Generic Complex Drug Substances and Formulations., 2017.
[27]
Berendt, R.T.; Samy, R.; Carlin, A.S.; Pendse, A.; Schwartz, P.; Khan, M.A.; Faustino, P.J. Spontaneous carbonate formation in an amorphous, amine-rich, polymeric drug substance: sevelamer HCl product quality. J. Pharm. Sci., 2012, 101(8), 2681-2685.
[http://dx.doi.org/10.1002/jps.23228] [PMID: 22700351]
[28]
Osterhout, J. L. Draft guidance on sevelamer carbonate.
[29]
Doty, A.C.; Zhang, Y.; Weinstein, D.G.; Wang, Y.; Choi, S.; Qu, W.; Mittal, S.; Schwendeman, S.P. Mechanistic analysis of triamcinolone acetonide release from PLGA microspheres as a function of varying in vitro release conditions. Eur. J. Pharm. Biopharm., 2017, 113, 24-33.
[http://dx.doi.org/10.1016/j.ejpb.2016.11.008] [PMID: 27865933]
[30]
Jain, S.K.; Jain, A.K.; Rajpoot, K. Expedition of eudragit® polymers in the development of novel drug delivery systems. Curr. Drug Deliv., 2020, 17(6), 448-469.
[http://dx.doi.org/10.2174/1567201817666200512093639] [PMID: 32394836]
[31]
Lim, Y.W.; Tan, W.S.; Ho, K.L.; Mariatulqabtiah, A.R.; Abu Kasim, N.H.; Abd Rahman, N.; Wong, T.W.; Chee, C.F. Challenges and complications of poly(lactic-co-glycolic acid)-based long-acting drug product development. Pharmaceutics, 2022, 14(3), 614.
[http://dx.doi.org/10.3390/pharmaceutics14030614] [PMID: 35335988]
[32]
Martín-Sabroso, C.; Fraguas-Sánchez, A.I.; Aparicio-Blanco, J.; Cano-Abad, M.F.; Torres-Suárez, A.I. Critical attributes of formulation and of elaboration process of PLGA-protein microparticles. Int. J. Pharm., 2015, 480(1-2), 27-36.
[http://dx.doi.org/10.1016/j.ijpharm.2015.01.008] [PMID: 25578370]
[33]
Cristofoletti, R.; Schmidt, S.; Diniz, A. Non-procrustean pathways for complex generic drugs development. Therap Del., 2018, 9(9), 605-607.
[http://dx.doi.org/10.4155/tde-2018-0047]
[34]
Cristofoletti, R.; Schmidt, S.; Diniz, A. Non-Procrustean Pathways for Complex Generic Drugs Development., 2018, 9(9), 605-607.
[http://dx.doi.org/10.4155/tde-2018-0047]
[35]
Di Francesco, T.; Philipp, E.; Borchard, G. Iron sucrose: assessing the similarity between the originator drug and its intended copies. Ann. N. Y. Acad. Sci., 2017, 1407(1), 63-74.
[http://dx.doi.org/10.1111/nyas.13517] [PMID: 29168243]
[36]
Pai, A.B. Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation. Ann. N. Y. Acad. Sci., 2017, 1407(1), 17-25.
[http://dx.doi.org/10.1111/nyas.13461] [PMID: 29027212]
[37]
Roberts, T.C.; Langer, R.; Wood, M.J.A. Advances in oligonucleotide drug delivery. Nat. Rev. Drug Discov., 2020, 19(10), 673-694.
[http://dx.doi.org/10.1038/s41573-020-0075-7] [PMID: 32782413]
[38]
Wang, L.; Wang, N.; Zhang, W.; Cheng, X.; Yan, Z.; Shao, G.; Wang, X.; Wang, R.; Fu, C. Therapeutic peptides: current applications and future directions. Signal Transduct. Target. Ther., 2022, 7(1), 48.
[http://dx.doi.org/10.1038/s41392-022-00904-4] [PMID: 35165272]
[39]
Wu, L.C.; Chen, F.; Lee, S.L.; Raw, A.; Yu, L.X. Building parity between brand and generic peptide products: Regulatory and scientific considerations for quality of synthetic peptides. Int. J. Pharm., 2017, 518(1-2), 320-334.
[http://dx.doi.org/10.1016/j.ijpharm.2016.12.051] [PMID: 28027918]
[40]
Knezevic, I.; Griffiths, E. WHO standards for biotherapeutics, including biosimilars: an example of the evaluation of complex biological products. Ann. N. Y. Acad. Sci., 2017, 1407(1), 5-16.
[http://dx.doi.org/10.1111/nyas.13434] [PMID: 28905423]
[41]
Zhang, C.; Yang, L.; Wan, F.; Bera, H.; Cun, D.; Rantanen, J.; Yang, M. Quality by design thinking in the development of long-acting injectable PLGA/PLA-based microspheres for peptide and protein drug delivery. Int. J. Pharm., 2020, 585, 119441.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119441] [PMID: 32442645]
[42]
Panchal, K.; Katke, S.; Dash, S.K.; Gaur, A.; Shinde, A.; Saha, N.; Mehra, N.K.; Chaurasiya, A. An expanding horizon of complex injectable products: Development and regulatory considerations. Drug Deliv. Transl. Res., 2023, 13(2), 433-472.
[http://dx.doi.org/10.1007/s13346-022-01223-5] [PMID: 35963928]
[43]
Andhariya, J.V.; Shen, J.; Choi, S.; Wang, Y.; Zou, Y.; Burgess, D.J. Development of in vitro-in vivo correlation of parenteral naltrexone loaded polymeric microspheres. J. Control. Release, 2017, 255, 27-35.
[http://dx.doi.org/10.1016/j.jconrel.2017.03.396] [PMID: 28385676]
[44]
Li, T.; Chandrashekar, A.; Beig, A.; Walker, J.; Hong, J.K.Y.; Benet, A.; Kang, J.; Ackermann, R.; Wang, Y.; Qin, B.; Schwendeman, A.S.; Schwendeman, S.P. Characterization of attributes and in vitro performance of exenatide-loaded PLGA long-acting release microspheres. Eur. J. Pharm. Biopharm., 2021, 158, 401-409.
[http://dx.doi.org/10.1016/j.ejpb.2020.10.008] [PMID: 33122118]
[45]
Shen, J.; Burgess, D.J. In vitro-in vivo correlation for complex non-oral drug products: Where do we stand? J. Control. Release, 2015, 219, 644-651.
[http://dx.doi.org/10.1016/j.jconrel.2015.09.052] [PMID: 26419305]
[46]
Pastorin, G.; Benetti, C.; Wacker, M.G. From in vitro to in vivo: A comprehensive guide to IVIVC development for long-acting therapeutics. Adv. Drug Deliv. Rev., 2023, 199, 114906.
[http://dx.doi.org/10.1016/j.addr.2023.114906] [PMID: 37286087]
[47]
Mohammed, D.; Matts, P.J.; Hadgraft, J.; Lane, M.E. In vitro-in vivo correlation in skin permeation. Pharm. Res., 2014, 31(2), 394-400.
[http://dx.doi.org/10.1007/s11095-013-1169-2] [PMID: 23943545]
[48]
Kang, H.N.; Thorpe, R.; Knezevic, I.; Casas Levano, M.; Chilufya, M.B.; Chirachanakul, P.; Chua, H.M.; Dalili, D.; Foo, F.; Gao, K.; Habahbeh, S.; Hamel, H.; Kim, G.H.; Perez Rodriguez, V.; Putri, D.E.; Rodgers, J.; Savkina, M.; Semeniuk, O.; Srivastava, S.; Tavares Neto, J.; Wadhwa, M.; Yamaguchi, T. Regulatory challenges with biosimilars: An update from 20 countries. Ann. N. Y. Acad. Sci., 2021, 1491(1), 42-59.
[http://dx.doi.org/10.1111/nyas.14522] [PMID: 33222245]
[49]
Klein, K.; Borchard, G.; Shah, V.P.; Flühmann, B.; McNeil, S.E.; de Vlieger, J.S.B. A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways. Ann. N. Y. Acad. Sci., 2021, 1502(1), 5-13.
[http://dx.doi.org/10.1111/nyas.14662] [PMID: 34296458]
[50]
Sauna, Z.E.; Lagassé, H.A.D.; Alexaki, A.; Simhadri, V.L.; Katagiri, N.H.; Jankowski, W.; Kimchi-Sarfaty, C. Recent advances in (therapeutic protein) drug development. F1000 Res., 2017, 6, 113.
[http://dx.doi.org/10.12688/F1000RESEARCH.9970.1/DOI]
[51]
Oduah, E.; Linhardt, R.; Sharfstein, S. Heparin: Past, Present, and Future. Pharmaceuticals, 2016, 9(3), 38.
[http://dx.doi.org/10.3390/ph9030038] [PMID: 27384570]
[52]
Heodore, W Induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. 1995, 332(20), 1330-1336.
[http://dx.doi.org/10.1056/NEJM199505183322003]
[53]
Hales, D.; Vlase, L.; Porav, S.A.; Bodoki, A.; Barbu-Tudoran, L.; Achim, M.; Tomuță, I. A quality by design (QbD) study on enoxaparin sodium loaded polymeric microspheres for colon-specific delivery. Eur. J. Pharm. Sci., 2017, 100, 249-261.
[http://dx.doi.org/10.1016/j.ejps.2017.01.006] [PMID: 28088371]
[54]
Fda; Cder. Contains nonbinding recommendations draft guidance on enoxaparin sodium. 2011.
[55]
Generic enoxaparin questions and answers | FDA. Available from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/generic-enoxaparin-questions-and-answers (Accessed 2023-05-25).
[56]
Fda; Cder; Winbourne. immunogenicity-related considerations for low molecular weight heparin guidance for industry. 2016.
[57]
Medicines Agency. E. Committee for Medicinal Products for Human (CHMP); Guideline on Non-Clinical and Clinical Development of Similar Biological Medicinal Products Containing Low-Molecular-Weight-Heparins Adopted by CHMP for Release for Consultation, 2016.
[58]
Genovese, S.; Mannucci, E.; Ceriello, A. A review of the long-term efficacy, tolerability, and safety of exenatide once weekly for type 2 diabetes. Adv. Ther., 2017, 34(8), 1791-1814.
[http://dx.doi.org/10.1007/s12325-017-0499-6] [PMID: 28674957]
[59]
Bridges, A.; Bistas, K.G.; Jacobs, T.F. Exenatide; StatPearls, 2022.
[60]
Fda. highlights of prescribing information. https://www.fda.gov/about-fda/oncology-center-excellence/how-do-i-use-prescription-drug-labeling 2002.
[61]
Fda; cder. exenatide synthetic subcutaneous extended release for suspension. https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022200.pdf 2002.
[62]
Medicines Agency. E. Committee for medicinal products for human use (CHMP) exenatide powder and solvent for prolonged-release suspension for injection, 2 mg, and powder and solvent for prolonged-release suspension for injection in pre-filled pen, 2 mg product-specific bioequivalence guidance. 2017.
[63]
Ballav, C.; Gough, S. Bydureon: Long-acting exenatide for once-weekly injection. Prescriber, 2012, 23(1-2), 30-33.
[http://dx.doi.org/10.1002/psb.852]
[64]
Lecube, A.; Bueno, M.; Suárez, X. Twice-daily and weekly exenatide: Clinical profile of two pioneer formulations in incretin therapy. Med. Clin., 2014, 143, 23-27.
[http://dx.doi.org/10.1016/S0025-7753(14)70105-8]
[65]
Liang, R.; Li, X.; Shi, Y.; Wang, A.; Sun, K.; Liu, W.; Li, Y. Effect of water on exenatide acylation in poly(lactide-co-glycolide) microspheres. Int. J. Pharm., 2013, 454(1), 344-353.
[http://dx.doi.org/10.1016/j.ijpharm.2013.07.012] [PMID: 23872225]
[66]
Bydureon Development at Alkermes: Interview with rajesh kumar | controlled release society. Available from: https://www.controlledreleasesociety.org/publications/crs-inside-track/bydureon-development-alkermes-interview-rajesh-kumar (Accessed 2023-04-01).
[67]
ICH reflection paper further opportunities for harmonization of standards for generic drugs 1. https://www.ich.org/page/reflection-papers2018.
[68]
FY 2022 gdufa science and research report | FDA. Available from: https://www.fda.gov/drugs/generic-drugs/fy-2022-gdufa-science-and-research-report (Accessed 2023-05-25).
[69]
FDA-EMA Parallel Scientific Advice Pilot Program for Complex Generic/Hybrid Products | FDA. Available from: https://www.fda.gov/drugs/generic-drugs/fda-ema-parallel-scientific-advice-pilot-program-complex-generichybrid-products (Accessed 2023-05-25).
[70]
5 September pilot program: Ema-fda parallel scientific advice for hybrid/complex generic products-general principles. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/pilot-programme-european-medicines-agency-food-drug-administration-parallel-scientific-advice-hybrid/complex-generic-products-general-principles_en.pdf2021.
[71]
Thor, S.; Vetter, T.; Marcal, A.; Kweder, S. EMA-FDA parallel scientific advice: Optimizing development of medicines in the global age. Ther. Innov. Regul. Sci., 2023, 57(4), 656-661.
[http://dx.doi.org/10.1007/s43441-023-00501-9] [PMID: 36871110]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy